
浏览全部资源
扫码关注微信
1.东南大学附属中大医院溧水分院/南京市溧水区人民医院超声医学科,江苏 南京 211200
2.东南大学附属中大医院溧水分院/南京市溧水区人民医院病理科,江苏 南京 211200
3.悉尼大学医学与健康学院,澳大利亚 新南威尔士 2050
常新,E-mail:changxincx4@163.com
纸质出版日期:2024-02-25,
收稿日期:2023-01-10,
扫 描 看 全 文
汪金,常新,韩春荣等.超声造影联合血清SMURF1检测诊断甲状腺癌的临床分析[J].局解手术学杂志,2024,33(02):153-156.
WANG Jin,CHANG Xin,HAN Chun-rong,et al.Clinical analysis of contrast-enhanced ultrasound combined with serum SMURF1 detection in the diagnosis of thyroid cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(02):153-156.
汪金,常新,韩春荣等.超声造影联合血清SMURF1检测诊断甲状腺癌的临床分析[J].局解手术学杂志,2024,33(02):153-156. DOI: 10.11659/jjssx.01E023048.
WANG Jin,CHANG Xin,HAN Chun-rong,et al.Clinical analysis of contrast-enhanced ultrasound combined with serum SMURF1 detection in the diagnosis of thyroid cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(02):153-156. DOI: 10.11659/jjssx.01E023048.
目的
2
探讨超声造影联合血清Smad泛素调节因子1(SMURF1)检测对甲状腺癌的诊断价值。
方法
2
纳入东南大学附属中大医院溧水分院2019年2月至2020年2月收治的144例疑似甲状腺癌患者为研究对象,根据组织病理学结果,将其分为甲状腺癌组(76例)和良性组(68例)。所有患者均行超声造影检查及血清SMURF1水平测定;分析超声造影参数、血清SMURF1单独检测及二者联合检测对甲状腺癌的诊断价值。
结果
2
甲状腺癌组超声造影参数峰值强度(PI)、平均灌注强度(SImean)及最大灌注强度(SImax)均低于良性组,SMURF1 mRNA水平高于良性组(
P
<
0.05)。超声造影参数SImax诊断甲状腺癌的敏感度为82.89%,特异度为72.06%,准确度为77.78%,
Kappa
值为0.552。血清SMURF1诊断甲状腺癌的敏感度为65.79%,特异度为94.12%,准确度为79.17%,
Kappa
值为0.589。SImax联合SMURF1诊断的敏感度、特异度、准确度、
Kappa
值分别为97.37%、85.29%、91.67%、0.832,均高于SImax、SMURF1单独诊断(
P
<
0.05),且二者联合预测预后的
AUC
为0.927,明显高于二者单独诊断(
Z
联合
vs.
SImax
=3.999,
P
<
0.001;
Z
联合
vs.
SMURF1
=
3.270,
P
=0.001)。
结论
2
超声造影联合血清SMURF1检测可提高甲状腺癌的诊断效能,可在保证甲状腺癌患者诊断效率的前提下,避免临床甲状腺癌患者的过度诊断。
Objective
2
To investigate the diagnostic value of contrast-enhanced ultrasound (CEUS) combined with serum Smad ubiquitin regulatory factor 1 (SMURF1) detection for thyroid cancer.
Methods
2
A total of 144 suspected thyroid cancer patients admitted to Lishui branch of Zhongda Hospital Affiliated to Southeast University from February 2019 to February 2020 were selected as the study subjects. Based on the histopathological results,they were divided into the thyroid cancer group (76 cases) and the benign group (68 cases). All patients underwent contrast-enhanced ultrasound examination and serum SMURF1 level detection; the diagnostic value of contrast-enhanced ultrasound parameters,serum SMURF1 detection alone,and the combination of the two methods for thyroid cancer were analyzed.
Results
2
Contrast-enhanced ultrasound parameters peak intensity(PI),mean perfusion intensity(SImean) and maximum perfusion intensity(SImax) in the thyroid cancer group were lower than those in the benign group,and the level of SMURF1 mRNA was higher than that in the benign group (
P
<
0.05). The sensitivity of contrast-enhanced ultrasound parameter SImax in the diagnosis of thyroid cancer was 82.89%,the specificity was 72.06%,the accuracy was 77.78%,and the
Kappa
value was 0.552. The sensitivity of serum SMURF1 in the diagnosis of thyroid cancer was 65.79%,the specificity was 94.12%,the accuracy was 79.17%,and the
Kappa
value was 0.589. The sensitivity,specificity,accuracy and
Kappa
value of SImax combined with serum SMURF1 in the diagnosis of thyroid cancer were 97.37%,85.29%,91.67% and 0.832,respectively,which were higher than those of SImax and SMURF1 alone (
P
<
0.05),the
AUC
of the combination of the two methods was 0.927,which was significantly higher than that of the two methods alone (
Z
combined
vs.
SImax
=3.999,
P
<
0.001;
Z
combined
vs.
SMURF1
=3.270,
P
=0.001).
Conclusion
2
Contrast-enhanced ultrasound combined with serum SMURF1 detection can improve the diagnostic efficiency of thyroid cancer,which may avoid the over-diagnosis on the premise of ensuring the effective diagnosis of thyroid cancer patients.
甲状腺癌超声造影Smad泛素调节因子1诊断
thyroid cancercontrast-enhanced ultrasoundSmad ubiquitin regulatory factor 1diagnosis
Seib CD,Sosa JA.Evolving understanding of the epidemiology of thyroid cancer[J].Endocrinol Metab Clin North Am,2019,48(1):23-35.doi:10.1016/j.ecl.2018.10.002http://dx.doi.org/10.1016/j.ecl.2018.10.002.
Sorrenti S,Dolcetti V,Fresilli D,et al.The role of CEUS in the evaluation of thyroid cancer:from diagnosis to local staging[J].J Clin Med,2021,10(19):4559.doi:10.3390/jcm10194559http://dx.doi.org/10.3390/jcm10194559.
李冰茹,关新全,李剑秋.甲状腺癌超声诊断及误诊分析[J].局解手术学杂志,2005,4(3):196-197.doi:10.3969/j.issn.1672-5042. 2005.03.046http://dx.doi.org/10.3969/j.issn.1672-5042.2005.03.046
董文武,张浩.持续或复发性分化型甲状腺癌再手术疗效及其影响因素[J].中国实用外科杂志,2021,41(8):868-871.doi:10.19538/j.cjps.issn1005-2208.2021.08.07http://dx.doi.org/10.19538/j.cjps.issn1005-2208.2021.08.07.
Riesco-Eizaguirre G,Santisteban P.Endocrine tumours: advances in the molecular pathogenesis of thyroid cancer:lessons from the cancer genome[J].Eur J Endocrinol,2016,175(5):R203-R217.doi:10.1530/EJE-16-0202http://dx.doi.org/10.1530/EJE-16-0202.
Feng X,Jia Y,Zhang Y,et al.Ubiquitination of UVRAG by SMURF1 promotes autophagosome maturation and inhibits hepatocellular carcinoma growth[J].Autophagy,2019,15(7):1130-1149.doi:10.1080/15548627.2019.1570063http://dx.doi.org/10.1080/15548627.2019.1570063.
Wei X,Wang X,Zhan J,et al.Smurf1 inhibits integrin activation by controlling Kindlin-2 ubiquitination and degradation[J].J Cell Biol,2017,216(5):1455-1471.doi:10.1083/jcb.201609073http://dx.doi.org/10.1083/jcb.201609073.
Fan X,Wang Y,Fan J,et al.Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop[J].J Cell Biochem,2019,120(6):10643-10651.doi:10.1002/jcb.28354http://dx.doi.org/10.1002/jcb.28354.
Jiang M,Shi L,Yang C,et al.miR-1254 inhibits cell proliferation,migration,and invasion by down-regulating Smurf1 in gastric cancer[J].Cell Death Dis,2019,10(1):32.doi:10.1038/s41419-018-1262-xhttp://dx.doi.org/10.1038/s41419-018-1262-x.
Yan C,Su H,Song X,et al.Smad Ubiquitination Regulatory Factor 1 (Smurf1) promotes thyroid cancer cell proliferation and migration via ubiquitin-dependent degradation of kisspeptin-1[J].Cell Physiol Biochem,2018,49(5):2047-2059.doi:10.1159/000493715http://dx.doi.org/10.1159/000493715.
Sparano C,Verdiani V,Pupilli C,et al.Choosing the best algorithm among five thyroid nodule ultrasound scores:from performance to
cytology sparing-a single-center retrospective study in a large cohort[J].Eur Radiol,2021,31(8):5689-5698.doi:10.1007/s00330-021-07703-5http://dx.doi.org/10.1007/s00330-021-07703-5.
Wan P,Chen F,Liu C,et al.Hierarchical temporal attention network for thyroid nodule recognition using dynamic CEUS imaging[J].IEEE Trans Med Imaging,2021,40(6):1646-1660.doi:10.1109/TMI.2021.3063421http://dx.doi.org/10.1109/TMI.2021.3063421.
张芳,李新,王海龙.超声造影参数对甲状腺癌的鉴别及其病情进展的评估价值[J].实用癌症杂志,2022,37(1):77-79.doi:10.3969/j.issn.1001-5930.2022.01.021http://dx.doi.org/10.3969/j.issn.1001-5930.2022.01.021.
Jiang J,Shang X,Zhang H,et al.Correlation between maximum intensity and microvessel density for differentiation of malignant from benign thyroid nodules on contrast-enhanced sonography[J].J Ultrasound Med,2014,33(7):1257-1263.doi:10.7863/ultra. 33.7.1257http://dx.doi.org/10.7863/ultra.33.7.1257.
黄莺,李奇林,张存程,等.超声造影定量参数联合血清TSHR mRNA用于甲状腺癌老年患者临床诊断的价值[J].中国老年学杂志,2019,39(11):2631-2634.doi:doi:10.3969/j.issn.1005-9202. 2019.11.021http://dx.doi.org/doi:10.3969/j.issn.1005-9202.2019.11.021.
王春梅,王利利.超声造影参数与分化型甲状腺癌肿瘤组织中增殖基因表达及淋巴结转移的关联性分析[J].影像科学与光化学,2020,38(6):1076-1081.doi:10.7517/issn.1674-0475.200521http://dx.doi.org/10.7517/issn.1674-0475.200521.
李梅,郑绥丽,刘楚,等.甲状腺癌患者CEUS特征及参数变化研究[J].影像科学与光化学,2022,40(4):773-777.doi:10.7517/issn.1674-0475.220507http://dx.doi.org/10.7517/issn.1674-0475.220507.
Rajabi S,Dehghan MH,Dastmalchi R,et al.The roles and role-players in thyroid cancer angiogenesis[J].Endocr J,2019,66(4):277-293.doi:10.1507/endocrj.EJ18-0537http://dx.doi.org/10.1507/endocrj.EJ18-0537.
Xia Q,Li Y,Han D,et al.SMURF1,a promoter of tumor cell progression?[J].Cancer Gene Ther,2021,28(6):551-565.doi:10.1038/s41417-020-00255-8http://dx.doi.org/10.1038/s41417-020-00255-8.
Bian S.miR-4319 inhibited the development of thyroid cancer by modulating FUS-stabilized SMURF1[J].J Cell Biochem,2020,121(1):174-182.doi:10.1002/jcb.29026http://dx.doi.org/10.1002/jcb.29026.
王卉,赵珊珊,姚劲草,等.超声联合甲状腺球蛋白检测对甲状腺癌术前N分期的价值分析[J].中华超声影像学杂志,2022,31(2):122-128.doi:10.3760/cma.j.cn131148-20210727-00500http://dx.doi.org/10.3760/cma.j.cn131148-20210727-00500.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621